Lestaurtinib

Lestaurtinib

Lestaurtinib (rINN, codenamed CEP-701) is a tyrosine kinase inhibitor structurally related to staurosporine, and is being developed by Cephalon.

It is an inhibitor of FLT3,<ref name="pmid16857985">Knapper S, Burnett AK, Littlewood T, et al.,

 A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy, 
 Blood, 
 
 Vol. 108(Issue: 10),
 pp. 3262–70,
 DOI: 10.1182/blood-2006-04-015560,
 PMID: 16857985,
 
 
 Full text,</ref> JAK2,<ref name="pmid17984313">Hexner EO, Serdikoff C, Jan M, et al., 
 Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders, 
 Blood, 
 
 Vol. 111(Issue: 12),
 pp. 5663–71,
 DOI: 10.1182/blood-2007-04-083402,
 PMID: 17984313,
 PMC: 2424161,
 
 Full text,</ref> TrkA, TrkB and TrkC.<ref>Revill, P., Serradell, N., Bolos, J., Rosa, E., 
 Lestaurtinib, 
 Drugs of the Future, 
 2007,
 Vol. 32(Issue: 3),
 pp. 215,
 DOI: 10.1358/dof.2007.032.03.1084137,</ref>

Uses

It is undergoing research for the treatment of acute myelogenous leukemia (AML) and myeloproliferative disorders.

As of 2009, it is in Phase II clinical trials for AML and Phase II clinical trials for myeloproliferative disorders.<ref>

Oncology pipeline Oct 2009(link). {{{website}}}.

</ref><ref>

Trials of Lestaurinib(link). {{{website}}}.

</ref>

See also

• Janus kinase inhibitor

References

This article is a stub related to pharmacology. You can help WikiMD by expanding it!